Advertisement Pharmaceutical Business review - Page 119 of 5217 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
July 26, 2024

Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies

Belgium-based Confo Therapeutics has secured €60m ($65m) in a Series B financing round to propel its pipeline of G protein-coupled receptor (GPCR)-modulating therapies into clinical development.

This funding will enable the advancement of programmes, including molecules aimed at GPR75 for treating obesity.  Credit: Vidmir Raic from Pixabay.